Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Status:
RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The main questions it aims to answer are:
Does IB-FOLFIRI improve clinical outcomes compared with historical outcomes in this population?
What is the safety profile of IB-FOLFIRI in patients with BRAF V600E-mutant mCRC?
Participants will:
Receive Iparomlimab and Tuvonralimab, bevacizumab, and FOLFIRI every two weeks
Have blood samples and/or tumor tissue collected for biomarker analysis (e.g., ctDNA sequencing)
Undergo regular imaging and clinical evaluations to assess treatment response and safety